Literature DB >> 21508297

Prevalence of lipodystrophy and dyslipidemia among patients with HIV infection on generic ART in rural South India.

Annie Phoebe Kalyanasundaram1, Saramma Mini Jacob, Ramachandran Hemalatha, Mampakkam Rajappa Sivakumar.   

Abstract

As antiretroviral therapy (ART) becomes more available to the HIV-infected population, it is important to determine the prevalence of its long-term complications. In this cross-sectional study, 145 HIV-positive patients on ART, 146 HIV-positive patients not on ART, and 72 HIV-negative individuals visiting the Namakkal District Head Quarters Hospital, Tamil Nadu, India, were recruited from February 2007 to April 2009. Among the patients on ART, the prevalence of lipodystrophy was 60.7%; 22.7% with lipohypertrophy, 51.1% with lipoatrophy, and 22.7% with mixed pattern. The proportion of patients with dyslipidemia was significantly higher in the treatment group when compared to ART-naive and HIV-negative controls (P = .00). Total duration of ART was significantly associated with lipodystrophy (P = .04) and dyslipidemia (P = .01). Also, by logistic regression, abnormal metabolic levels were a risk factor in lipodystrophy (P = .02). This study highlights the need for development of inexpensive and accessible treatments for the reduction of lipodystrophy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21508297     DOI: 10.1177/1545109711401750

Source DB:  PubMed          Journal:  J Int Assoc Physicians AIDS Care (Chic)        ISSN: 1545-1097


  8 in total

1.  Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India.

Authors:  Euden Bhutia; Alok Hemal; Tribhuvan Pal Yadav; K L Ramesh
Journal:  Afr Health Sci       Date:  2014-06       Impact factor: 0.927

2.  Diabetes mellitus and risk factors in human immunodeficiency virus-infected individuals at Jimma University Specialized Hospital, Southwest Ethiopia.

Authors:  Abdurehman Eshete Mohammed; Tilahun Yemane Shenkute; Waqtola Cheneke Gebisa
Journal:  Diabetes Metab Syndr Obes       Date:  2015-04-15       Impact factor: 3.168

3.  Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon.

Authors:  Dickson Shey Nsagha; Elroy Patrick Weledji; Nguedia Jules Clement Assob; Longdoh Anna Njunda; Elvis Asangbeng Tanue; Odette Dzemo Kibu; Charlotte Wenze Ayima; Marcelin Ngowe Ngowe
Journal:  BMC Cardiovasc Disord       Date:  2015-08-28       Impact factor: 2.298

Review 4.  HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings.

Authors:  Julia L Finkelstein; Pooja Gala; Rosemary Rochford; Marshall J Glesby; Saurabh Mehta
Journal:  J Int AIDS Soc       Date:  2015-01-15       Impact factor: 5.396

5.  Cardiovascular Disease and Cardiovascular Disease Risk in HIV-Positive Populations in the Asian Region.

Authors:  Rimke Bijker; Jun Yong Choi; Rossana Ditangco; Sasisopin Kiertiburanakul; Man Po Lee; Sarawut Siwamogsatham; Sanjay Pujari; Jeremy Ross; Chi-Yuen Wong; Wing-Wai Wong; Evy Yunihastuti; Matthew Law
Journal:  Open AIDS J       Date:  2017-08-21

6.  Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study.

Authors:  Agete Tadewos; Zelalem Addis; Henock Ambachew; Sandip Banerjee
Journal:  AIDS Res Ther       Date:  2012-10-25       Impact factor: 2.250

7.  Prevalence of lipodystrophy and metabolic syndrome among HIV positive individuals on Highly Active Anti-Retroviral treatment in Jimma, South West Ethiopia.

Authors:  Tsegay Berhane; Alemishet Yami; Fessahaye Alemseged; Tilahun Yemane; Leja Hamza; Mehedi Kassim; Kebede Deribe
Journal:  Pan Afr Med J       Date:  2012-10-30

8.  Increased trunk fat along with decreased peripheral fat as an important predictor of hypertriglyceridaemia & hypercholesterolaemia in Indians with HIV infection.

Authors:  Deep Dutta; Meha Sharma; Atul Anand; Umesh Chandra Garga; Rahul Bansal; Neera Sharma
Journal:  Indian J Med Res       Date:  2018-10       Impact factor: 2.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.